Earnings per share for the last twelve months: Personalis Inc (PSNL)
Genomic sequencing costs and the implementation of MRD tests are creating financial pressure, as evidenced by the 12-month earnings per share history, where the current level sits around -1.17. Personalis, Inc. (PSNL) can achieve optimization through its NeXt Personal AI platform for early screening and its status as a recognized scientific leader in high-sensitivity analysis, which strengthens the trust of major medical centers.
Analytical breakdowns and data insights for company Personalis Genomics (PSNL)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- net income and valuation multiples indicators:
PSNL - Company Profit|Projected Future Earnings Personalis, Inc.|PSNL - P/E Multiple|Future Price to Earnings Personalis Corp|PSNL - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Personalis|PSNL - Operating income before deduction of amortization|Earnings per share for the last twelve months Personalis|PSNL - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months personalis.com|PSNL - Earnings per share increase in current year|Earnings growth forecast for next year Personalis, Inc.
- revenue and sales proceeds data:
General company analysis:PSNL - Personalis Inc
Personalis, Inc. (PSNL) monetization of genetic data arrays through contracts with pharma giants directly impacts the business's bottom-line profitability, reflecting the efficiency of converting intellectual capital into actual revenue. This metric is calculated as the ratio of net income to the number of shares, and analyzing the rolling annual net income per share on GURU.Markets allows for the timely identification of trend degradation to ensure prompt portfolio rebalancing.
Competitors of Personalis, Inc.
ONC - Earnings per share for the last twelve months|HALO - Net earnings per share (EPS TTM)|RevMed (RVMD) - Earnings per share for the last twelve months|Ascentage - Earnings per share for the trailing year|CGON (CG Oncology Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma URGN|Net earnings per share (EPS TTM) BCAX|ERAS - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) DCTH (delcath.com)|Net earnings per share for the trailing year Y-mAbs Corp|AURA - Earnings per share for the last twelve months|CADL (candeltx.com) - Earnings per share for the last 12 months|ARAY (accuray.com) - Net earnings per share for the last 12 months|SELLAS Life Sciences Group Inc. (SLS) - Net earnings per share (EPS TTM)|ACTU (Actuate Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Citius Oncology Inc|Net earnings per share (EPS TTM) HURA|TARA (Protara Therapeutics) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) FATE (Fate Therapeutics)|Net earnings per share for the last four quarters Aadi Bioscience Inc (WHWK)|TScan Therapeutics, Inc. - Net earnings per share (EPS TTM)|CSBR (Champions Oncology, Inc.) - Earnings per share for the last 12 months|XBIT (XBiotech USA) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months CEL-SCI Corp (CVM)|OSTX (OS Therapies Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Radiopharm Theranostics (RADX)|Net earnings per share for the last 12 months ARTV (Artiva Biotherapeutics, Inc.)|ANL - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Veru Inc. VERU|Earnings per share for the trailing year TPST|XLO: Net earnings per share for the last 12 months|Net earnings per share for the last four quarters Renovaro RENB|MURA (muraloncology.com) - Net earnings per share for the last 12 months|Kairos Pharma Inc - Earnings per share for the trailing year|Net earnings per share for the last 12 months OKUR|Net earnings per one share for the last twelve months CytoMed Therapeutics Limited GDTC|Net earnings per share (EPS TTM) CRIS|Net earnings per share (EPS TTM) Apollomics Inc. (APLM)|Net earnings per share (EPS TTM) THAR (Tharimmune Corp)|Net earnings per share for the last four quarters Advanced Biomed Inc (ADVB)|Genprex Inc - Net earnings per share (EPS TTM)|CLDI - Net earnings per share (EPS TTM)|Sunshine Biopharma Inc. (SBFM) - Earnings per share for the last twelve months|XBIO - Net earnings per share for the last four quarters|SLRX (Salarius Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Kitov Pharma|Net earnings per share for the last 12 months AONC (American Oncology Network)|BGNE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CKPT (Checkpoint Therapeutics Inc.)|Elevation Oncology, Inc. - Earnings per share for the last twelve months|ICAD - Earnings per share for the last twelve months|IKNA - Net earnings per share (EPS TTM)|Notable Labs (NTBL) - Earnings per share for the last twelve months|Earnings per share for the last 12 months VIRX|MOR (MorphoSys Corporation) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NAYA Biosciences Inc NAYA|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
